Tag: QED Therapeutics

Home / QED Therapeutics

Categories

Infigratinib receives accelerated approval from the FDA for metastatic cholangiocarcinoma

August 2021: Infigratinib (Truseltiq, QED Therapeutics, Inc.), a kinase inhibitor, has been granted accelerated approval by the Food and Drug Administration for adults with previously treated, unresec...
qed-therapeutics

Scan the code